Af­ter stop­ping Farx­i­ga tri­al ear­ly, As­traZeneca de­clares suc­cess in CKD treat­ment

Back in March, As­traZeneca an­nounced plans to halt a Phase III tri­al for its Farx­i­ga drug ahead of sched­ule af­ter see­ing “over­whelm­ing ef­fi­ca­cy” in pa­tients with chron­ic kid­ney dis­ease. Now, the British drug­mak­er is claim­ing a win af­ter the drug met all pri­ma­ry and sec­ondary end­points.

The tri­al con­firmed Farx­i­ga, an SGLT2 in­hibitor used to treat adults with type 2 di­a­betes, helped halt kid­ney dis­ease pro­gres­sion. As­traZeneca tracked a com­pos­ite pri­ma­ry end­point that com­bined mea­sure­ments on whether re­nal func­tion im­proved and whether the drug re­duced the risk of re­nal fail­ure. The tri­al hit that end­point.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN